Breaking News

Tweet TWEET

Innovative Technologies that Yield Improved Treatments - Research Report on Mettler-Toledo, Ironwood, Covance, Teleflex and

 Innovative Technologies that Yield Improved Treatments - Research Report on
             Mettler-Toledo, Ironwood, Covance, Teleflex and WuXi

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, June 26, 2013

NEW YORK, June 26, 2013 /PRNewswire/ --

Today, Wall Street Reports announced new research reports highlighting
Mettler-Toledo International, Inc. (NYSE: MTD), Ironwood Pharmaceuticals Inc.
(NASDAQ: IRWD), Covance Inc. (NYSE: CVD), Teleflex Incorporated (NYSE: TFX)
and WuXi PharmaTech (Cayman) Inc. (NYSE: WX). Today's readers may access these
reports free of charge - including full price targets, industry analysis and
analyst ratings - via the links below.

Mettler-Toledo International, Inc. Research Report

On June 20, 2013, Mettler-Toledo International, Inc. (Mettler-Toledo)
announced that it has released two new titration brochures, the "Selected
Titration Methods for the Food and Beverages Industry", and the thoroughly
revised Karl Fischer Applications Brochure "Methods for Water Content
Determination". The releases aim to assist laboratory personnel in method
development and implementation. It also explains the chemistry behind Karl
Fischer, food and beverage titrations and give practical advice for sample and
reagent handling. As per the Company, the Food and Beverage (F&B) industry is
subject to regulations covering the entire production process for the benefit
of food safety, consumer protection and international trade. And hence, well
defined analytical reference methods are needed at all stages of the
production process and content determination by titration is a widely used
analytical technique. The Full Research Report on Mettler-Toledo
International, Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:
http://www.WSReports.com/r/full_research_report/a364_MTD]

--

Ironwood Pharmaceuticals Inc. Research Report

On June 13, 2013, Ironwood Pharmaceuticals Inc. (Ironwood) along with
Almirall, S.A., announced the launch of Constella, the first approved
prescription therapy in a new class of treatments for adults suffering from
moderate to severe IBS-C (Irritable Bowel Syndrome with Constipation) in
Europe. "The availability of linaclotide is excellent news for the one-third
of adult IBS patients that have constipation. The symptoms associated with the
condition can negatively impact the lives of patients. A targeted prescription
treatment specifically for IBS-C is extremely welcome for both appropriate
patients and physicians alike who can now better manage this unpleasant,
chronic condition", said Professor Eamonn Quigley, Gastroenterologist. The
Company informed that Constella is now available in Germany, the UK and Nordic
countries and is expected to be launched in several other European countries
in 2013. The Full Research Report on Ironwood Pharmaceuticals Inc. - including
full detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.wsreports.com/r/full_research_report/d5cb_IRWD]

--

Covance Inc. Research Report

On June 18, 2013, Covance Inc. (Covance) announced that a partnership between
the Company and Battle Creek Unlimited received the Best New Partnership,
Merger or Acquisition Award at the 2013 Nutraceutical Business & Technology
Awards, held recently in Geneva, Switzerland. Covance and Battle Creek
Unlimited were recognized for an innovative partnership that is helping to
promote excellence in food science, shape the next generation of food
scientists and help transform Battle Creek into a food science, innovation and
growth-oriented community. The Full Research Report on Covance Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.wsreports.com/r/full_research_report/5499_CVD]

--

Teleflex Incorporated Research Report

On June 10, 2013, Teleflex Inc. (Teleflex) announced that it has received FDA
510(k) clearance to market ARROW NextStep Retrograde Femoral Length Dialysis
Catheters, which is designed for clinical ease of insertion and sustained high
flow rates. "Providing clinicians with the ARROW NextStep Femoral Length
Catheters continues a series of new product introductions that demonstrates
our commitment to enhance patient outcomes and improve ease of use for
clinicians," said Linda Beneze, President and General Manager, Specialty
Division, Teleflex. Teleflex asserts that ARROW NextStep Retrograde Femoral
Length Catheters further strengthens the NextStep Hemodialysis Catheter
portfolio of the Company. The Full Research Report on Teleflex Incorporated -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.wsreports.com/r/full_research_report/9f7f_TFX]

--

WuXi PharmaTech (Cayman) Inc. Research Report

On June 16, 2013 WuXi PharmaTech (Cayman) Inc. (WuXi) announced that Ambrx and
Zhejiang Medicine Co. Ltd. (ZMC) have formed a collaboration to develop and
commercialize ARX788, Ambrx's most advanced internally developed site-specific
antibody drug conjugate (ADC) targeting Her2-positive breast cancer. As per
the agreement, WuXi will provide integrated services for ARX788, including the
development and manufacturing of the toxin, antibody and ADC, pre-clinical
development and clinical trials. "Our collaboration with Ambrx and ZMC on
ARX788 is another example of how WuXi's comprehensive, integrated, open-access
R&D services platform enables our partners to develop innovative products
efficiently and cost-effectively to benefit the world's patients," said Dr. Ge
Li, Chairman and Chief executive Officer of WuXi. "We are very pleased to
offer our partners integrated services at global standards ranging from toxins
to antibodies, from CMC development to pre-clinical studies, from regulatory
strategy to clinical trials." The Full Research Report on WuXi PharmaTech
(Cayman) Inc. - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:
[http://www.wsreports.com/r/full_research_report/d375_WX]

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by a CFA. However, we are only human and are prone to
    make mistakes. If you notice any errors or omissions, please notify us
    below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider has, through Chartered Financial
Analysts, only reviewed the information provided by Equity News Network in
this article or report according to the Procedures outlined by Equity News
Network. Equity News Network is not entitled to veto or interfere in the
application of such procedures by the outsourced provider to the articles,
documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

SOURCE Wall Street Reports

Contact: WSReports.com Phone #: +1-310-496-8071 (North America)
 
Press spacebar to pause and continue. Press esc to stop.